Generic Name:
Afatinib
Project Status:
Complete
Therapeutic Area:
Advanced or Metastatic Non-Small Cell Lung Cancer
Manufacturer:
Boehringer Ingelheim Canada Ltd.
Brand Name:
Giotrif
Project Line:
Reimbursement Review
Project Number:
PC0032-000
NOC Date:
Details
Strength:
20mg, 30mg, and 40mg tablets
Tumour Type:
Lung
Indications:
Advanced Non Small Cell Lung Cancer
Funding Request:
For the first line treatment of EGFR Mutation Positive, Advanced Non-Small Cell Lung Cancer patients
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Boehringer Ingelheim Canada Ltd.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Clarification:
A delay in the receipt of Category 2 Part 2 requirements has impacted the review timeline.
Recommendation Type:
Reimburse
Clarification:
A delay in the receipt of Category 2 Part 2 requirements has impacted the review timeline.
Funding Request:
For the first line treatment of EGFR Mutation Positive, Advanced Non-Small Cell Lung Cancer patients
pERC Meeting:
Final Recommendation Issued: